Organization | Hospital Duran i Reynals

Hospital Duran i Reynals Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2011

NCT03887442

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Institut Català d´Oncologia-Duran i Reynals | Instituto Catalán de Oncología. Hospital Duran i Reynals

Active Ingredients

Drugs in Phase 3 Trials (6)

bevacizumab (avastin) (1 trial)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (2 trials)

panitumumab (vectibix) (1 trial)

Drugs in Phase 2 Trials (5)

cetuximab (erbitux) (1 trial)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colorectal Neoplasms (Phase 3)

Head and Neck Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 11